2004•PsychopharmacologyRequires access

Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition

Will Spooren, Cédric Mombereau, M. Maco, R. Gill, JohnA. Kemp, Laurence Ozmen, Shigetada Nakanishi, GuyA. Higgins

Open publisher page 29 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 29 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Dizocilpine, NMDA receptor, Prepulse inhibition, Glutamate receptor, Pharmacology, Receptor, Antagonist, Chemistry

Back to paper search Browse research topics Original source

Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition — Research Paper | ScholarLens